Expanding Nutraceutical Portfolio Cosm's introduction of the science-driven '18 Series' with clinically validated products positions the company to capitalize on the growing consumer demand for proven health solutions. This creates opportunities to cross-sell complementary nutraceutical items and expand into new health categories.

Strong U.S. Market Entry The rapid acceleration of Cosm's U.S. expansion, including product launches like Liv18 and Cur18, indicates increased market traction and consumer interest. Sales teams can leverage these developments to build partnerships with health retailers, pharmacies, and direct-to-consumer channels.

Strategic Production Capabilities With GMP-certified, FDA-registered manufacturing facilities in the U.S., Cosm is well-positioned to offer reliable supply chains for large-scale distribution. This robustness can attract bulk orders from distributors and retail chains seeking quality-assured health supplements.

Innovative Technology Utilization Cosm's ongoing AI integration aimed at improving efficiency and reducing costs suggests potential for advanced data-driven sales strategies. Partnering with Cosm for customized product development or analytics services could open new revenue streams.

Financial Growth & Investment The company's record-breaking 2025 revenue of $65.3 million and substantial funding of $250 million highlight strong financial health and growth intent. This financial backing creates opportunities for joint ventures, co-marketing efforts, and expanding distribution networks globally.